Recent progress of Src family kinase inhibitors as anticancer agents

被引：18

作者：

Cao, Xin ^{[1
]}

You, Qi-Dong ^{[1
]}

Li, Zhi-Yu ^{[1
]}

Wang, Xiao-Jian ^{[1
]}

Lu, Xiao-Yun ^{[1
]}

Liu, Xiao-Rong ^{[1
]}

Xu, Dan ^{[1
]}

Liu, Bao ^{[1
]}

机构：

[1] China Pharmaceut Univ, Dept Med Chem, Jiangsu Key Lab Carcinogenesis & Intervent, Nanjing 210009, Jiangsu, Peoples R China

来源：

MINI-REVIEWS IN MEDICINAL CHEMISTRY | 2008年 / 8卷 / 10期

基金：

中国国家自然科学基金;

关键词：

protein tyrosine kinases; Src family kinases; kinase domain; inhibitor; anticancer; drug design; SH2; SH3;

D O I：

10.2174/138955708785740634

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Src family of protein tyrosine kinases (SFKs) play key roles in regulating signal transduction in cellular processes. However, hyper-activated SFKs lead to uncontrolled cell proliferation and cancers. Many SFKs inhibitors were designed and synthesized as anticancer agents in the past several years and great progress has been made. Herein, some predominant examples of SFKs inhibitors recently developed are reviewed and special attentions are paid to the most important ATP binding site inhibitors.

引用

收藏

页码：1053 / 1063

页数：11

相关论文

共 82 条

[1] 8-anilinoimidazo[4,5-g]quinoline-7-carbonitriles as Src kinase inhibitors [J].

Berger, D ;

Dutia, M ;

Powell, D ;

Wu, BQ ;

Wissner, A ;

DeMorin, F ;

Weber, J ;

Boschelli, F .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2002, 12 (19) :2761-2765

[2]

Biscardi JS, 1998, MOL CARCINOGEN, V21, P261, DOI 10.1002/(SICI)1098-2744(199804)21:4<261::AID-MC5>3.0.CO

[3]

2-N

[4]

Biscardi JS, 1999, ADV CANCER RES, V76, P61

[5] EARLY ACTIVATION OF ENDOGENOUS PP60SRC KINASE-ACTIVITY DURING NEURONAL DIFFERENTIATION OF CULTURED HUMAN NEUROBLASTOMA-CELLS [J].

BJELFMAN, C ;

MEYERSON, G ;

CARTWRIGHT, CA ;

MELLSTROM, K ;

HAMMERLING, U ;

PAHLMAN, S .

MOLECULAR AND CELLULAR BIOLOGY, 1990, 10 (01) :361-370

[6] Structure and regulation of Src family kinases [J].

Boggon, TJ ;

Eck, MJ .

ONCOGENE, 2004, 23 (48) :7918-7927

[7] SOLUTION STRUCTURE AND LIGAND-BINDING SITE OF THE SH3 DOMAIN OF THE P85-ALPHA SUBUNIT OF PHOSPHATIDYLINOSITOL 3-KINASE [J].

BOOKER, GW ;

GOUT, I ;

DOWNING, AK ;

DRISCOLL, PC ;

BOYD, J ;

WATERFIELD, MD ;

CAMPBELL, ID .

CELL, 1993, 73 (04) :813-822

[8] Optimization of 4-phenylamino-3-quinolinecarbonitriles as potent inhibitors of Src kinase activity [J].

Boschelli, DH ;

Ye, F ;

Wang, YD ;

Dutia, M ;

Johnson, SL ;

Wu, BQ ;

Miller, K ;

Powell, DW ;

Yaczko, D ;

Young, M ;

Tischler, M ;

Arndt, K ;

Discafani, C ;

Etienne, C ;

Gibbons, J ;

Grod, J ;

Lucas, J ;

Weber, JM ;

Boschelli, F .

JOURNAL OF MEDICINAL CHEMISTRY, 2001, 44 (23) :3965-3977

[9] Investigation of the effect of varying the 4-anilino and 7-alkoxy groups of 3-quinolinecarbonitriles on the inhibition of Src kinase activity [J].

Boschelli, DH ;

Fe, Y ;

Wu, BQ ;

Wang, YD ;

Sosa, ACB ;

Yaczko, D ;

Powell, D ;

Golas, JM ;

Lucas, J ;

Boschelli, F .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2003, 13 (21) :3797-3800

[10] Identification of 7-phenylaxaminothieno[3,2-b]pyridine-6-carbonitriles as a new class of Src kinase inhibitors [J].

Boschelli, DH ;

Wu, BQ ;

Sosa, ACB ;

Durutlic, H ;

Ye, F ;

Raifeld, Y ;

Golas, JM ;

Boschelli, F .

JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (27) :6666-6668

← 1 2 3 4 5 6 7 8 9 →